Brian Woodard

Cooley advised Archon Biosciences, a biotechnology company pioneering computationally designed antibody cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, on its $20 million seed financing led by Madrona Ventures.

Cooley advised Outpace Bio, a cell therapy company using unrivaled artificial intelligence-powered protein design to program immune cells for improved function inside patients battling solid tumors, on its $144 million oversubscribed Series B financing.

Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).

Cooley advised World View, a leader in stratospheric exploration and flight, on its definitive business combination agreement with publicly traded special purpose acquisition company Leo Holdings Corp. II. The transaction will result in World View becoming a publicly listed company. Partners Alex Kassai, Milson Yu and Miguel Vega led the Cooley team advising World View.

Cooley advised Bonum Therapeutics, a biopharmaceutical company focused on creating highly active and less toxic medicines, on its $93 million Series A financing. Partner Sonya Erickson led the Cooley team advising Bonum Therapeutics.